TP53 mutations in human cancers: origins, consequences, and clinical use
about
The spectrum of SWI/SNF mutations, ubiquitous in human cancersMicroRNAs in the DNA Damage/Repair Network and CancerA Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to TumorigenesisYour neighbours matter - non-autonomous control of apoptosis in development and diseaseTargeting Oncogenic Mutant p53 for Cancer TherapyP53 functional abnormality in mesenchymal stem cells promotes osteosarcoma developmentOncogenic MicroRNAs: Key Players in Malignant TransformationDNA repair and aging: the impact of the p53 familyMutant p53: Multiple Mechanisms Define Biologic Activity in Cancer"Liquid biopsy"-ctDNA detection with great potential and challengesReactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumorsEmerging and Evolving Ovarian Cancer Animal ModelsProtein Folding and Mechanisms of ProteostasisSequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic LandscapesMEG3 noncoding RNA: a tumor suppressorAlternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progressionNOD-Like Receptors: Master Regulators of Inflammation and CancerThe genetic and epigenetic alterations in human hepatocellular carcinoma: a recent updateAnalysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acidGetting TRAIL back on track for cancer therapyThe p53-estrogen receptor loop in cancerStructural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactionsThe rebel angel: mutant p53 as the driving oncogene in breast cancer.Role of DNA repair machinery and p53 in the testicular germ cell cancer: a reviewImmunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor MicroenvironmentSynthetic lethality in lung cancer and translation to clinical therapiesEmerging Non-Canonical Functions and Regulation by p53: p53 and StemnessP53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemiap53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Conceptp53 Acetylation: Regulation and ConsequencesGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRJdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosityConnecting molecular pathways to hereditary cancer risk syndromesTP53 and lacZ mutagenesis induced by 3-nitrobenzanthrone in Xpa-deficient human TP53 knock-in mouse embryo fibroblastsp53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening systemInactivation and inducible oncogenic mutation of p53 in gene targeted pigsModified Proofreading PCR for Detection of Point Mutations, Insertions and Deletions Using a ddNTP-Blocked PrimerTranscriptome analysis of tetraploid cells identifies cyclin D2 as a facilitator of adaptation to genome doubling in the presence of p53Methyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosisSwitching off malignant mesothelioma: exploiting the hypoxic microenvironment
P2860
Q21090801-85D080C4-15A5-4ACC-9196-C52976CDB404Q21284509-8058C62F-F7C1-4B0A-88F1-079CEB06197AQ26746952-B265EF02-48B8-41EE-87C8-0239815C94DFQ26749610-AE332F8C-2ED1-41D4-92FD-360B7CBD8528Q26770856-0F32D48F-0618-4F7A-B412-4215C895539CQ26771603-953462D5-8B08-417E-AA03-4DD06F83C8C4Q26773316-C82D76D1-F3A6-4461-A830-02086EAACA73Q26775866-6254F5B0-7B47-418F-8086-8FDC3B2D9997Q26776020-0C2F055D-9335-426B-96DB-D753F29EA270Q26779222-FD6B9A74-43AD-4A9E-8D70-2F3AABA31388Q26783710-E12E8321-A6DB-4A75-AE28-62B0BB4D276BQ26783909-5B7261C2-B69A-4F27-84A0-9EAC67772C47Q26801512-1A1D1E06-2252-4C2D-A336-F8A971CBE883Q26801785-BAEBEFFF-210B-425C-B8B9-58E0B9569EDEQ26823948-C7859B60-35F6-4326-8CBD-637AFF526CC4Q26862886-3EEF2814-54AB-4F0F-AE94-9BF1BD178003Q26865199-576530D6-059F-4A69-9BDB-565D47FD9CFAQ27003050-BC9FF2E2-31E4-43F0-9535-8B23BC3B2740Q27021933-3A827C8F-C7AA-4EAD-BC4F-B1731C6E089BQ27027460-BEE0CC7C-A943-4D52-AFBF-17B457269B30Q27027865-A2A5A55D-EC69-4B6B-8B84-68B0EF53E4AEQ27679121-C8E457C9-9081-48A9-8F77-11C4D78D74FDQ27686765-8032DAB6-0535-4675-B453-B1179BE78532Q28069963-D86C71F8-5E72-4A5A-B09E-00886B192FCCQ28071935-D2FC80B6-2C6A-4B5E-AB7A-0C7CD3236FCAQ28072904-2D55F5ED-C0A2-4A80-ADAC-6DB1E7C68368Q28077156-D38DC2A8-CEBB-45B8-9409-EDE2BC1BEBA2Q28078609-628EEFFD-A62F-4C49-A3A4-01757C4219C6Q28079390-D8144170-430D-4427-9C8C-D4C625CCB866Q28085076-499777CC-EF3F-4306-8C91-70ABFE8950CBQ28086993-DC07DBF4-9262-4DD7-83E9-96826F4ACBA8Q28260776-AA631437-387D-42CA-AB56-E084B7AA57C7Q28291516-885E488F-34E0-4DA7-A980-725F49D26199Q28390021-FFA98C43-8C99-476C-901B-D3E7B9EC2114Q28478414-D77D5B10-7326-4034-BAF0-856973A2E82DQ28484241-3C2F87C7-5163-41AE-ACEF-2004D08F693EQ28546764-E4D1438F-72BD-443C-A238-9115029250F5Q28552677-C76E22EE-747E-41D8-ABAD-C9EF2D7D3A7DQ28658683-53985E95-B523-4CB4-A422-2E90AF88BD08Q29248727-59E19372-BB2E-4003-AC62-FB176603B377
P2860
TP53 mutations in human cancers: origins, consequences, and clinical use
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
TP53 mutations in human cancers: origins, consequences, and clinical use
@ast
TP53 mutations in human cancers: origins, consequences, and clinical use
@en
type
label
TP53 mutations in human cancers: origins, consequences, and clinical use
@ast
TP53 mutations in human cancers: origins, consequences, and clinical use
@en
prefLabel
TP53 mutations in human cancers: origins, consequences, and clinical use
@ast
TP53 mutations in human cancers: origins, consequences, and clinical use
@en
P2860
P1476
TP53 mutations in human cancers: origins, consequences, and clinical use
@en
P2093
Magali Olivier
Monica Hollstein
P2860
P304
P356
10.1101/CSHPERSPECT.A001008
P577
2010-01-01T00:00:00Z